← Back to Screener
Upstream Bio, Inc. Common Stock (UPB)
Price$10.10
Favorite Metrics
Price vs S&P 500 (26W)-51.77%
Price vs S&P 500 (4W)8.20%
Market Capitalization$537.67M
All Metrics
Book Value / Share (Quarterly)$6.26
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)33.04%
Cash Flow / Share (Quarterly)$-2.46
Price vs S&P 500 (YTD)-66.25%
Net Profit Margin (TTM)-5026.03%
EPS (TTM)$-2.66
10-Day Avg Trading Volume0.58M
EPS Excl Extra (TTM)$-2.66
EPS (Annual)$-2.66
ROI (Annual)-42.22%
Cash / Share (Quarterly)$6.30
Revenue Growth QoQ (YoY)8.97%
ROA (Last FY)-40.55%
Revenue Growth TTM (YoY)20.42%
EBITD / Share (TTM)$-2.97
Operating Margin (TTM)-5618.82%
Cash Flow / Share (Annual)$-2.46
P/B Ratio1.58x
P/B Ratio (Quarterly)4.32x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)152.80x
ROA (TTM)-35.38%
EPS Incl Extra (Annual)$-2.66
Current Ratio (Annual)26.15x
Quick Ratio (Quarterly)26.02x
3-Month Avg Trading Volume1.08M
52-Week Price Return30.34%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)188.39x
Asset Turnover (Annual)0.01x
52-Week High$33.68
EPS Excl Extra (Annual)$-2.66
26-Week Price Return-47.78%
Quick Ratio (Annual)26.02x
13-Week Price Return-68.79%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)26.15x
Enterprise Value$436.091
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-5026.03%
Cash / Share (Annual)$6.30
3-Month Return Std Dev135.62%
Net Income / Employee (TTM)$-3
ROE (Last FY)-42.22%
EPS Basic Excl Extra (Annual)$-2.66
Receivables Turnover (TTM)4.46x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.66
Receivables Turnover (Annual)4.46x
ROI (TTM)-36.48%
P/S Ratio (TTM)188.39x
Revenue / Share (Annual)$0.05
Price vs S&P 500 (52W)0.51%
Year-to-Date Return-63.61%
5-Day Price Return-5.18%
EPS Normalized (Annual)$-2.66
Net Profit Margin (Annual)-5026.03%
Month-to-Date Return9.78%
EBITD / Share (Annual)$-2.97
Operating Margin (Annual)-5618.82%
EPS Basic Excl Extra (TTM)$-2.66
P/B Ratio (Annual)4.32x
Pretax Margin (TTM)-5026.03%
Book Value / Share (Annual)$6.26
Price vs S&P 500 (13W)-69.48%
Beta0.97x
Revenue / Share (TTM)$0.05
ROE (TTM)-36.48%
52-Week Low$7.22
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.08
4.08
4.08
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
UPBUpstream Bio, Inc. Common Stock | 188.39x | 20.42% | — | — | $10.10 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Upstream Bio is a clinical-stage biotechnology company developing verekitug, a TSLP receptor antagonist for inflammatory diseases. The company is initially targeting severe respiratory disorders where TSLP is a validated pathological driver. This upstream target addresses multiple immune-mediated disease indications.